Zanubrutinib Associated With Cost Savings and QALY Benefits vs Acalabrutinib in B-Cell Malignancies
ATRA/ATO Regimen Improves EFS in Newly Diagnosed, High-risk APL
Glofitamab Plus Gemcitabine/Oxaliplatin Shows Survival Benefit in Transplant-Ineligible R/R DLBCL
Dr Bertossi on the Prognostic Role of TP53 Mutations in CLL